VAERS reports by lot

Merck HPV lot 1522U: VAERS reports

63 VAERS reports list lot 1522U as a Merck HPV vaccine, received between 2007-12-05 and 2017-04-27. Data: VAERS public files through 31 December 2024 (site extract 2026-07-04).

Read this first. VAERS accepts reports from anyone, and a report does not establish that the vaccine caused the event. A lot's report count mostly reflects how many doses it contained, when it was used and who received it; no administered-dose counts are published for this lot, so counts are not rates and cannot rank lots against each other. Lot numbers in VAERS reports are typed by reporters and are sometimes wrong.
63
Reports
49%
Marked serious
0
With a death outcome
24
Months with reports

Symptom categories in these reports

A report can mention several categories, so the counts add up to more than the number of reports.

CategoryCount%
General / Systemic (non-local)5622%
Neurological5220%
Gastrointestinal3815%
Cardiac / Cardiovascular2711%
Musculoskeletal2610%
Injection-site / Local reaction197%
Dermatological (non-injection-site)187%
Allergic / Anaphylactic94%
Psychiatric / Neuropsychiatric52%
Autoimmune / Immune-mediated21%
Thrombotic / Hematological10%
Respiratory10%
Reproductive / Menstrual10%

Where reports came from

U.S. state of the reporter, where given (top 12).

Pennsylvania11
Massachusetts5
Maryland4
North Carolina4
New Jersey4
Missouri3
Texas3
Florida2
Georgia2
Connecticut2
Arkansas2
Washington1

Reports by month received

2007-125
2008-0113
2008-027
2008-035
2008-042
2008-051
2008-062
2008-075
2008-084
2008-092
2008-104
2008-121
2009-011
2009-031
2009-041
2009-051
2009-101
2010-051
2010-091
2011-061
2011-071
2013-031
2014-011
2017-041

Products recorded with this lot

Manufacturer and product as reported in VAERS. Reports listing the lot under more than one product are counted once.

Related

Source: VAERS public data (CDC/FDA), grouped by manufacturer and lot by the Open Source Medicine Foundation; extract 2026-07-04 16:35 UTC. Not medical advice. Report errors via contact.